InvestorsHub Logo
Followers 51
Posts 9121
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Monday, 11/07/2022 10:32:18 AM

Monday, November 07, 2022 10:32:18 AM

Post# of 91
November and December news in release!!!! Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma


CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.

but we will have more new data and a new cohort of 11 patients in December this year."

https://www.healthleadersmedia.com/pharma/just-two-years-helm-ceo-paul-peter-tak-transforms-candel-and-cancer-treatment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CADL News